Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

While children under five, particularly those under two, are the most vulnerable, pneumococcal diseases also affect adults.

Invasive Pneumococcal Disease Market Outlook 2025-2035: The 7 major invasive pneumococcal disease markets reached a value of USD 6.6 Billion in 2024. Looking forward, IMARC Group expects the 7MM to ...

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for ...

A 21-valent pneumococcal conjugate vaccine was economically favorable and reduced the burden of pneumococcal disease in vaccine-naive older adult patients. V116, a 21-valent pneumococcal conjugate ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Pregnant patients in their third trimester and postpartum women showed higher risk for IPD compared with nonpregnant patients.

(1) Chronic kidney disease (CKD) poses a significant burden on patients across all stages, with immune dysfunction contributing to a heightened vulnerability to infections. As CKD progresses, immune ...